Firouz Daneshgari1, Edward H Leiter, Guiming Liu, Jay Reeder. 1. Department of Urology and Female Pelvic Surgery, State University of New York, Upstate Medical University, Syracuse, New York, USA. firouz.daneshgari@case.edu
Abstract
PURPOSE: Diabetes mellitus is a group of debilitating and costly diseases with multiple serious complications. Lower urinary tract complications or diabetic uropathy are among the most common complications of diabetes mellitus, surpassing widely recognized complications such as neuropathy and nephropathy. Diabetic uropathy develops in individuals with types 1 and 2 diabetes, and little is known about the natural history of these common and troublesome complications. Animal models have the potential to reveal mechanisms and aid in the development of treatment strategies. MATERIALS AND METHODS: We present a review of available animal models of diabetes mellitus relative to their use in the study of diabetic uropathy. RESULTS: Large and small animal models of diabetes mellitus are available. While large animals such as dogs and swine may closely mirror the human disease in size and phenotype, the time between diabetic complication onset and development, and associated husbandry expenditures can make acquiring data on statistically valid sample sizes prohibitively expensive. In contrast, small animal models (rats and mice) have much lower expenditures for a larger number of animals and compressed observation time due to a shorter life span. Also, mice are readily manipulated genetically to facilitate the isolation of the effect of single genes (transgenic and knockout mice). Type 1 diabetes mellitus can be induced chemically with streptozotocin, which is selectively toxic to pancreatic beta cells. Type 2 diabetes mellitus models have been developed by selective breeding for hyperglycemia with or without associated obesity. Diabetic uropathy has been noted in several well characterized, predictable animal models of diabetes mellitus. CONCLUSIONS: Diabetic uropathy, including diabetic bladder dysfunction, has been more frequently studied in small animals with type I diabetes. The recent availability of transgenic models provides a new opportunity for further studies of diabetic uropathy in mouse models of types I and II diabetes mellitus.
PURPOSE:Diabetes mellitus is a group of debilitating and costly diseases with multiple serious complications. Lower urinary tract complications or diabetic uropathy are among the most common complications of diabetes mellitus, surpassing widely recognized complications such as neuropathy and nephropathy. Diabetic uropathy develops in individuals with types 1 and 2 diabetes, and little is known about the natural history of these common and troublesome complications. Animal models have the potential to reveal mechanisms and aid in the development of treatment strategies. MATERIALS AND METHODS: We present a review of available animal models of diabetes mellitus relative to their use in the study of diabetic uropathy. RESULTS: Large and small animal models of diabetes mellitus are available. While large animals such as dogs and swine may closely mirror the human disease in size and phenotype, the time between diabetic complication onset and development, and associated husbandry expenditures can make acquiring data on statistically valid sample sizes prohibitively expensive. In contrast, small animal models (rats and mice) have much lower expenditures for a larger number of animals and compressed observation time due to a shorter life span. Also, mice are readily manipulated genetically to facilitate the isolation of the effect of single genes (transgenic and knockout mice). Type 1 diabetes mellitus can be induced chemically with streptozotocin, which is selectively toxic to pancreatic beta cells. Type 2 diabetes mellitus models have been developed by selective breeding for hyperglycemia with or without associated obesity. Diabetic uropathy has been noted in several well characterized, predictable animal models of diabetes mellitus. CONCLUSIONS:Diabetic uropathy, including diabetic bladder dysfunction, has been more frequently studied in small animals with type I diabetes. The recent availability of transgenic models provides a new opportunity for further studies of diabetic uropathy in mouse models of types I and II diabetes mellitus.
Authors: Arun K Changolkar; Joseph A Hypolite; Michael Disanto; Peter J Oates; Alan J Wein; Samuel Chacko Journal: J Urol Date: 2005-01 Impact factor: 7.450
Authors: Enoka P Wijekoon; Beatrice Hall; Shobhitha Ratnam; Margaret E Brosnan; Steven H Zeisel; John T Brosnan Journal: Diabetes Date: 2005-11 Impact factor: 9.461
Authors: Kim N Danforth; Mary K Townsend; Karen Lifford; Gary C Curhan; Neil M Resnick; Francine Grodstein Journal: Am J Obstet Gynecol Date: 2006-02 Impact factor: 8.661
Authors: Martin Haluzik; Carlo Colombo; Oksana Gavrilova; Streamson Chua; Nicole Wolf; Min Chen; Bethel Stannard; Kelly R Dietz; Derek Le Roith; Marc L Reitman Journal: Endocrinology Date: 2004-04-01 Impact factor: 4.736
Authors: Matt S Conover; Ana L Flores-Mireles; Michael E Hibbing; Karen Dodson; Scott J Hultgren Journal: J Vis Exp Date: 2015-06-23 Impact factor: 1.355
Authors: Charles R Powell; Albert Kim; Joshua Roth; James P Byrd; Khalid Mohammad; Mouhamad Alloosh; Ragini Vittal; Michael Sturek Journal: Comp Med Date: 2020-09-24 Impact factor: 0.982